LIVE Price Database Suppliers B2B suppliers Quality & badges Encyclopedia Articles
LONGEVITY TOPICS
NAD+ Precursors Sirtuin Activators Senolytics Autophagy Mitochondrial Hormesis
About PeptideCompare Business Network Contact Policy
Home / Encyclopedia / Khavinson Bioregulators / Vesilut
MONOGRAPH No. 064
EVIDENCE BASELimited
TYPE
Natural peptide complex (cytomedin)
SEQUENCE
Proprietary complex
CAS
Not assigned
EU STATUS
Research only
WADA
Not listed
MIN PURITY
Lab-specific
Khavinson Bioregulators

Vesilut — EU research guide.

Vesilut is a Khavinson-series peptide bioregulator originally derived from urinary bladder tissue, studied for bladder cell function and urogenital aging research. It overlaps in proposed target tissue with Chitomur, another bladder-focused bioregulator in the same family.

Last reviewed:

What is Vesilut?

Vesilut is a Khavinson-series peptide bioregulator originally derived from urinary bladder tissue, studied for bladder cell function and urogenital aging research. It overlaps in proposed target tissue with Chitomur, another bladder-focused bioregulator in the same family.

What does the research show?

No primary animal, cell or human study of Vesilut could be verified; the only sourced items are a computational modelling paper and a single-arm abstract on a different bladder peptide complex. No independently replicated controlled human trials are publicly available as of mid-2026.

EU legal status

Not approved as a medicine anywhere in the EU. Available only from a small number of specialist research vendors.

⚠ Overlaps closely with Chitomur in proposed function — check the exact product specification rather than relying on category labels when comparing vendor listings.
✓ Not yet tracked in PeptideCompare's price comparison. Verify any vendor's COA and sequence/identity claims directly before ordering — see our COA guide.
EVIDENCE SUMMARY
NO HUMAN DATA
No primary study of Glu-Asp (Vesilut) located — The only source that ties Vesilut to a sequence is a 2016 modelling paper from the Khavinson group, which lists Vesilute as the dipeptide Glu-Asp (ED) and predicts weak DNA binding (about -3 kcal/mol). No cell, animal or human study of the compound under this name could be verified.
LIMITED
Related bladder peptide complex Vezusten (single-arm abstract, not Vesilut) — A 2025 conference abstract reports an open-label, single-arm study in 48 patients with overactive bladder using Vezusten, described as a bovine bladder peptide complex: 21 days of therapy and 21 days of follow-up, with symptom scores improving and night-time urination frequency falling 2.7-fold. This is a different, natural-extract product and should not be read as evidence for the synthetic dipeptide.

Molecular information

CAS number
Not assigned

Pharmacokinetics

No established human pharmacokinetic data. Published human PK parameters for this compound are not available; reported data are limited to animal models or absent. No curve is shown, to avoid implying data that does not exist.

Potency retained over time

Each line is one storage condition: it starts at 100% and declines as potency is lost. Above the dotted 80% line the material is considered reliable — hover the chart for exact values.

Freezer −20 °C
36+ mo
Stable · >95% potency
Fridge 4 °C
5-7 mo
In use · post-recon
Room 20 °C
3-4 wks
Limited · moderate loss
Warm 37 °C+
2-3 days
Poor · rapid loss

⚠ Estimates modelled per component from molecular properties (chain length, cyclisation, oxidation- and deamidation-sensitive residues, light sensitivity). Indicative only — not lab-measured per batch.

Vesilut is not yet in our price comparison

We expand EU supplier coverage every month.

References

  1. Modelling paper by the Khavinson group that lists Vesilute as the dipeptide Glu-Asp and predicts weak DNA binding. Computational only, and the sole verified link between the name and a sequence. Khavinson VKh, Lin'kova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016;162(2):288-292. DOI
  2. Conference abstract on Vezusten, a bovine bladder peptide complex, in 48 overactive-bladder patients (open-label, no control group). It concerns a natural extract, not Vesilut, and is included only because the page describes Vesilut as bladder-derived. Galkina N, Galkin A. Bioactive peptides in the treatment of overactive bladder (abstract 99). Continence. 2025. Source

Related guides

Khavinson Bioregulators

Bolamin
Khavinson Bioregulators

Bronchogen
Khavinson Bioregulators

Cardiogen
PeptideCompare AssistantOnline · replies instantly
Hi! I help you quickly find the right page — about legality, COAs, badges or suppliers. No price advice, no dosing.
Try a question
Find a supplier Questions about a peptide? Read our articles Compare prices Is this legal in the EU? How to read a COA What do badges mean? Will customs stop my order? What is BAC water? Talk to a doctor first?
Navigation assistant · no medical advice